NASDAQ: SABS
SAB Biotherapeutics, Inc.
Healthcare · Biotechnology
After hours: $4.04(+1%) · as of 7:57 PM ET
Per-share valuation inputs need verification
Event dated Mar 31, 2026Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$38.23M
52w High
$6.60
52w Low
$1.67
P/E
18.48
Volume
2.36M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 124.72% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow declined 69.56% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Company profile
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies built upon human antibodies.
Valuation
Stock splits
Every 10 shares became 1
Profitability & growth
Analyst consensus
7
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 6, 2026
Q3 FY26 · EPS est -$0.29 · Revenue est $125K
View